XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating Costs and Expenses:        
General and administrative $ 1,303,000 $ 1,197,000 $ 3,988,000 $ 3,876,000
Research and development 1,972,000 914,000 5,021,000 4,152,000
Total Operating Costs and Expenses 3,275,000 2,111,000 9,009,000 8,028,000
Loss from Operations (3,275,000) (2,111,000) (9,009,000) (8,028,000)
Other Income :        
Interest income 2,000 0 4,000 44,000
Total Other Income 2,000 0 4,000 44,000
Net Loss (3,273,000) (2,111,000) (9,005,000) (7,984,000)
Net Loss Attributable to Non-controlling Interest 0 (8,000) (1,000) (50,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (3,273,000) (2,103,000) (9,004,000) (7,934,000)
Effect of Series A Preferred Stock Price adjustment     (7,402,000) 0
Net Loss Attributable to Common Stockholders $ (3,273,000) $ (2,686,000) $ (17,926,000) $ (9,438,000)
Net Loss Per Share - Basic $ (0.02) $ (0.14) $ (0.15) $ (0.52)
Net Loss Per Share - Dilutive $ (0.02) $ (0.14) $ (0.15) $ (0.52)
Weighted average number of shares outstanding during the period - Basic 132,042,538 19,398,339 118,448,633 18,302,585
Weighted average number of shares outstanding during the period - Dilutive 132,042,538 19,398,339 118,448,633 18,302,585
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ 0 $ (64,000) $ (24,000) $ (189,000)
Effect of Series A Preferred Stock Price adjustment 0 0 (7,402,000) 0
Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest   100,000 100,000 100,000
Preferred Stock Dividends, Income Statement Impact 0 (519,000) $ (1,496,000) $ (1,315,000)
Preferred Stock [Member] | Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest   0    
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ 0 $ 0